Patient tailored anti-tumour T cells to prevent relapse in patients with acute myeloid leukaemia undergoing allogeneic haemopoietic stem cell transplantation
Patient tailored anti-tumour T cells to prevent relapse in patients with acute myeloid leukaemia undergoing allogeneic haemopoietic stem cell transplantation
批准号:
nhmrc : GNT1089398
负责人:
Dr Emily Blyth
金额:
$18.47万
依托单位国家:
澳大利亚
项目类别:
Early Career Fellowships
财政年份:
2015
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2015-01-01 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults. Patients with high-risk AML have a 2-year survival of less than 20%. Blood or bone marrow transplant from a healthy donor is often the only chance of cure but the leukaemia frequently returns. Dr Blyth will perform a clinical trial giving leukaemia fighting immune cells from the transplant donor to patients with high risk AML to prevent relapse after transplant.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A trial of tumour antigen targeted donor T cells in high risk acute myeloid leukaemia
-
批准号:nhmrc : GNT1088118
-
项目类别:Project Grants
-
资助金额:$39.13万
-
财政年份:2015
-
负责人:Dr Emily Blyth
-
依托单位:
Patient tailored anti-tumour T cells to prevent relapse in patients with acute myeloid leukaemia undergoing allogeneic haemopoietic stem cell transplantation
-
批准号:nhmrc : 1089398
-
项目类别:Early Career Fellowships
-
资助金额:$12.7万
-
财政年份:2015
-
负责人:Dr Emily Blyth
-
依托单位:
A trial of tumour antigen targeted donor T cells in high risk acute myeloid leukaemia
-
批准号:nhmrc : 1088118
-
项目类别:Project Grants
-
资助金额:$26.94万
-
财政年份:2015
-
负责人:Dr Emily Blyth
-
依托单位:
海外基金